ANN ARBOR, Ml / ACCESSWIRE / May 12, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. Management will also be conducting one-on-one meetings with investors.
Company Webcast
The Company's webcast presentation will be available for viewing at 9:00 am ET on Thursday, May 18, 2023. The presentation will be available to the public via webcast at: https://wsw.com/webcast/lytham8/zom/1899450.
Panel Presentation
Additionally, Mr. Heaton will be participating in a panel titled, "The State of Animal Health." This panel, also to be conducted virtually, will be held on Thursday, May 18, 2023, at 5:00 pm ET. To access the panel, please visit: https://wsw.com/webcast/lytham8/panel5/2275875.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://www.lythampartners.com/spring2023invreg/.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
Last Trade: | US$0.12 |
Daily Volume: | 12,083,028 |
Market Cap: | US$117.590M |
November 27, 2024 November 14, 2024 November 08, 2024 November 07, 2024 October 24, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB